This signaling axis plays a functionally important role in tumor maintenance, which is likely underestimated by somatic mutation frequencies alone as everolimus (an mTOR inhibitor) significantly prolongs progression-free survival in patients with progressive advanced PanNETs compared to placebo-treated controls (Yao et al., 2011). The gene discussed is MTOR; the disease is neoplasm.